Browse the corpus

Adiposis dolorosa, or Dercum disease, is a rare, chronic adipose tissue disorder characterized by multiple painful subcutaneous lipomas distributed across various body regions. The condition often presents with accompanying symptoms such as fatigue, cognitive impairment, and mood disturbances, reflecting its complex neuropsychiatric component. Although the precise pathophysiology remains unclear, proposed mechanisms include autonomic nervous system dysfunction, microvascular inflammation, and abnormal lipid metabolism. The disease predominantly affects middle-aged women and may significantly impair physical function and psychological well-being. Because of its nonspecific presentation and overlap with other lipomatous disorders, misdiagnosis is common, often delaying appropriate management. Current therapeutic strategies emphasize symptomatic relief through pharmacologic pain control, psychological support, and, in select cases, surgical excision of painful lipomas. Early recognition and individualized treatment planning remain essential for optimizing comfort and improving the quality of life for affected individuals. Through participation in this course, the learner develops the knowledge and clinical reasoning skills necessary to identify, evaluate, and manage adiposis dolorosa effectively. The curriculum underscores the value of coordinated interprofessional collaboration among clinicians, dermatologists, pain specialists, psychiatrists, and surgeons in addressing the multifaceted challenges of this condition. Such collaboration fosters timely diagnosis, integrated treatment approaches, and shared decision-making that enhance physical and emotional outcomes. By mastering evidence-based interventions and communication strategies, the participant strengthens competencies in patient-centered care, ensuring that management is comprehensive, empathetic, and aligned with each individual’s unique needs. This interprofessional approach not only refines clinical judgment but also improves patient satisfaction and overall therapeutic success in managing adiposis dolorosa. Objectives: Identify the key clinical features, epidemiology, and proposed pathophysiological mechanisms of adiposis dolorosa. Differentiate adiposis dolorosa from other lipomatous and chronic pain disorders using evidence-based diagnostic criteria.

Through participation in this course, the learner develops the knowledge and clinical reasoning skills necessary to identify, evaluate, and manage adiposis dolorosa effectively. The curriculum underscores the value of coordinated interprofessional collaboration among clinicians, dermatologists, pain specialists, psychiatrists, and surgeons in addressing the multifaceted challenges of this condition. Such collaboration fosters timely diagnosis, integrated treatment approaches, and shared decision-making that enhance physical and emotional outcomes. By mastering evidence-based interventions and communication strategies, the participant strengthens competencies in patient-centered care, ensuring that management is comprehensive, empathetic, and aligned with each individual’s unique needs. This interprofessional approach not only refines clinical judgment but also improves patient satisfaction and overall therapeutic success in managing adiposis dolorosa. Objectives: Identify the key clinical features, epidemiology, and proposed pathophysiological mechanisms of adiposis dolorosa. Differentiate adiposis dolorosa from other lipomatous and chronic pain disorders using evidence-based diagnostic criteria. Evaluate current medical, surgical, and supportive care management strategies for patients with adiposis dolorosa. Develop interprofessional care plans that integrate the roles of primary care, pain specialists, dermatologists, psychiatrists, and surgeons to improve patient outcomes. Access free multiple choice questions on this topic.

Adiposis dolorosa, also known as Dercum disease, Ander syndrome, morbus Dercum, adipose tissue rheumatism, adiposalgia, or lipomatosis dolorosa, is a rare chronic disorder characterized by multiple painful subcutaneous growths of adipose tissue. First described in the late 1800s by American neurologist Francis Xavier Dercum, this condition is classified into 4 types: generalized diffuse (widespread painful adiposity without discrete lipomas), generalized nodular (diffuse pain accentuated around lipomas), localized nodular (pain localized to discrete lipomas), and juxta-articular (painful, solitary adipose tissue near large joints).[1][2] The diagnosis is clinical and one of exclusion, with proposed criteria including chronic pain of subcutaneous tissue for over 3 months in individuals who are overweight or obese, although these criteria require further validation. Pain is often disabling, resistant to standard analgesics, and accompanied by systemic manifestations such as weakness, depression, anxiety, cognitive impairment, sleep disturbances, palpitations, dyspnea, gastrointestinal complaints, fatigue, and joint pain. Pathologically, the disorder primarily affects subcutaneous adipose tissue, most commonly on the trunk, proximal extremities, and upper arms, with lesions that may be discrete or diffuse. Histology may reveal normal adipocytes, mild fibrosis, or inflammatory infiltrates, but no pathognomonic finding exists. The natural history is progressive, characterized by the gradual enlargement of lesions and worsening pain over time. Spontaneous remission is rare; symptoms tend to fluctuate but persist without intervention. While liposuction and surgical excision may temporarily reduce bulk and alleviate pain, recurrence is common, underscoring the importance of long-term, multidisciplinary management.

The exact cause of adiposis dolorosa remains unknown. Current hypotheses suggest a multifactorial origin involving nervous system dysfunction (abnormal pain processing or peripheral nerve involvement), endocrine and metabolic factors (hormonal dysregulation, insulin resistance), lymphovascular abnormalities (microvascular fragility, impaired lymphatic drainage), adipose tissue dysfunction (abnormal lipid storage or inflammatory activity), mechanical nerve compression by lipomas, and posttraumatic onset in some cases.[3] Chronic low-grade inflammation within adipose tissue has been reported, characterized by the infiltration of immune cells and upregulation of pro-inflammatory cytokines, which may contribute to the persistence of pain. Although a few case reports describe an autosomal dominant inheritance pattern with variable phenotypic expression, no consistent genetic mutation has been identified, and most cases appear sporadic. Current evidence suggests that adiposis dolorosa is more likely the result of complex interactions between metabolic, vascular, and neuroinflammatory pathways rather than a single gene defect.

Adiposis dolorosa is a rare disorder, and its true prevalence is unknown due to underrecognition and frequent misdiagnosis. Available case series and reviews suggest a strong predominance among women. The condition most often presents in middle-aged individuals, typically between 35 and 50, although cases have been documented from adolescence to older adulthood.[4] In the United States, no large-scale epidemiologic studies have been conducted, but published clinical reports indicate it is more common in individuals who are overweight or obese, possibly affecting those with metabolic comorbidities at higher rates. Worldwide, cases have been reported in Europe, Asia, the Middle East, and South America, with similar demographic patterns. Most available prevalence estimates are based on small regional cohorts or specialty clinic populations, making it difficult to quantify the global burden. The rarity of adiposis dolorosa and a lack of standardized diagnostic criteria likely contribute to the underreporting and delays in diagnosis across healthcare systems.

Histopathologic findings in adiposis dolorosa are nonspecific and may vary between patients. Many specimens show normal-appearing mature adipocytes without evidence of malignancy. In some cases, mild interstitial fibrosis, thickening of connective tissue septa, or perivascular and septal inflammatory infiltrates composed primarily of lymphocytes and macrophages are observed. Occasional cases demonstrate microvascular changes or evidence of small nerve fiber proliferation within the affected adipose tissue, supporting the hypothesis of neuroinflammatory involvement. Importantly, no pathognomonic histologic feature has been identified, and biopsy primarily excludes other conditions such as liposarcoma, panniculitis, or other adipose tissue tumors. Because histology may be normal despite significant clinical symptoms, diagnosis remains predominantly clinical.

Patients with adiposis dolorosa typically present with a gradual onset of chronic, often debilitating, pain localized to subcutaneous adipose tissue. The pain may be described as burning, aching, or stabbing and is frequently disproportionate to visible lesions. Symptoms often persist for more than 3 months and are resistant to standard analgesics. Many patients report associated fatigue, weakness, cognitive difficulties ("brain fog"), depression, anxiety, and sleep disturbances. A history of overweight or obesity is common, and some individuals report symptom onset following trauma, surgery, or periods of weight gain. On physical examination, the hallmark finding is tenderness over subcutaneous fat with or without palpable lipomas. Lesions most often involve the trunk, upper arms, buttocks, and thighs. Depending on the subtype, findings may range from diffuse adiposity with generalized tenderness (generalized diffuse type) to discrete, tender nodules (localized nodular type) or painful periarticular fat pads (juxta-articular type). The overlying skin is usually normal, with no signs of acute inflammation. In severe cases, pain may limit mobility and daily activities, and patients may exhibit an antalgic gait or guarded movement patterns.

Diagnosis of adiposis dolorosa is clinical and one of exclusion, guided by proposed criteria such as chronic subcutaneous pain lasting more than 3 months in individuals who are overweight or obese. No universally accepted national or international guidelines exist; however, consensus from the expert literature emphasizes the systematic history-taking and physical examination, combined with the appropriate use of ancillary tests to rule out mimics. No specific biomarkers for adiposis dolorosa—laboratory testing is directed toward excluding alternative etiologies. Mild elevations in erythrocyte sedimentation rate, cholesterol, or metabolic parameters (eg, in patients with metabolic syndrome) may be noted, but are nonspecific. Radiographic evaluation via ultrasound and MRI may be helpful. Ultrasound may reveal multiple small, oblong hyperechoic nodules within subcutaneous fat. MRI may demonstrate superficial fatty lesions with a characteristic "blush-like" increase in fluid signal within the affected subcutaneous adipose tissue.[5] However, imaging findings are not consistently visible in all subtypes. Although formal guidelines are lacking, expert consensus, most notably by Hansson et al, suggests using the combination of obesity and chronic painful adipose tissue as minimal diagnostic criteria, with imaging and lab assessments primarily serving to exclude differential diagnoses.[6]

Adiposis dolorosa remains an incurable and challenging-to-treat condition. No Food and Drug Administration-approved therapies exist, and formal national or international guidelines are lacking. Expert consensus and case series uniformly recommend an individualized, multidisciplinary approach that coordinates pain specialists, surgeons, rehabilitation clinicians, and mental health professionals to tailor treatment to patient needs, alleviate pain, and enhance quality of life. Medical and Procedural Interventions First-line pain control may include nonsteroidal anti-inflammatory drugs, opioids, and adjuvant agents, though responses are often inconsistent. Local anesthetic applications, such as 5% transdermal lidocaine patches, creams, or intravenous infusions, have provided temporary but substantial pain relief in select cases. Off-label agents, including methotrexate, infliximab, interferon-α-2, and corticosteroids, have been documented to provide benefit in case reports, although responses vary and mechanisms remain unclear. Novel and Advanced Therapies Deoxycholic acid injections into painful fat areas have demonstrated significant symptom reduction.[7] Ketamine infusions, electrostimulation, and spinal cord stimulators have shown promise in refractory pain scenarios.[8][9] Rapidly cycling hypobaric pressure therapy and frequency-rhythmic electrical modulation systems have also demonstrated analgesic and functional benefits in pilot studies, highlighting the potential of emerging modalities for select patients. Surgical Interventions Liposuction and minimal-incision lipectomy can provide temporary relief from pain and volume loss, although recurrence of fat nodules is common, reported in up to 50% of cases.[10] Surgical excision of nodules may alleviate focal symptoms in localized disease; however, it is not a curative treatment. These approaches are best integrated within a broader, coordinated care plan rather than as standalone solutions. Supportive and Multidisciplinary Strategies

Liposuction and minimal-incision lipectomy can provide temporary relief from pain and volume loss, although recurrence of fat nodules is common, reported in up to 50% of cases.[10] Surgical excision of nodules may alleviate focal symptoms in localized disease; however, it is not a curative treatment. These approaches are best integrated within a broader, coordinated care plan rather than as standalone solutions. Supportive and Multidisciplinary Strategies Given the variable therapeutic outcomes, long-term symptom management through a chronic pain care team is critical. This includes pharmacologic optimization, procedural analgesia, psychological support, physical therapy, and patient-centered functional goals. Interprofessional collaboration ensures that treatment is tailored to the individual, reduces care fragmentation, and empowers patients to participate actively in their own management. In conclusion, treatment of adiposis dolorosa is mainly symptomatic and often temporary. Meaningful improvement typically requires a combination of pharmacologic, procedural, and surgical strategies, delivered within a pain-focused, ethically grounded, interprofessional care model.

Adiposis dolorosa presents with chronic, painful adipose tissue and subcutaneous nodules, a pattern that overlaps with several other disorders. Therefore, accurate diagnosis depends on a comprehensive history, focused physical examination, and systematic exclusion of alternative causes. Lipedema: A chronic disorder characterized by symmetrical, bilateral accumulation of painful fat, most commonly in the lower extremities. Unlike adiposis dolorosa, lipedema spares the trunk and upper arms, does not involve discrete lipomas, and usually lacks the widespread neuropsychiatric symptoms associated with Dercum disease. Fibromyalgia: This is a generalized pain syndrome with tender points, fatigue, and sleep disturbance. Fibromyalgia lacks discrete lipomas or localized painful fat deposits but shares overlapping features such as fatigue, depression, and chronic pain. Familial multiple lipomatosis: This is an inherited condition marked by multiple subcutaneous nonpainful lipomas and a family history linked to mutations in the HMGA2 gene. Differentiating features include the absence of pain and systemic symptoms. Madelung disease (multiple symmetric lipomatosis): This disease is characterized by symmetric, nontender fatty masses around the neck, shoulders, and upper trunk, most often in men with a history of alcohol use. Pain is not a defining feature.[11] Panniculitis: This is an inflammatory disorder of subcutaneous fat presenting with tender nodules and erythematous overlying skin. Unlike adiposis dolorosa, panniculitis typically exhibits skin changes and often has elevated systemic inflammatory markers. Proteus syndrome: This syndrome is associated with activating AKT1 mutations, which cause lipomatosis with disproportionate tissue overgrowth. Primary psychiatric disorders: Depression and anxiety may resemble Dercum disease due to overlapping symptoms of fatigue, pain, and cognitive disturbance, though without subcutaneous nodules. Liposarcoma: Malignant adipose tumor that may present as a growing subcutaneous or deep mass. Pain is uncommon, but a biopsy is essential to exclude malignancy when there is rapid growth, firmness, or atypical imaging features. Benign adipose tumors (lipomas, angiolipomas, liposarcomas) may mimic the nodular form but are typically painless and isolated.

Liposarcoma: Malignant adipose tumor that may present as a growing subcutaneous or deep mass. Pain is uncommon, but a biopsy is essential to exclude malignancy when there is rapid growth, firmness, or atypical imaging features. Benign adipose tumors (lipomas, angiolipomas, liposarcomas) may mimic the nodular form but are typically painless and isolated. Other mimicking conditions include obesity-related pain syndromes, neurofibromatosis with painful nodules, and endocrine or metabolic disorders such as Cushing syndrome and hypothyroidism, which may present with generalized adiposity and fatigue. The key distinguishing features of adiposis dolorosa are the presence of painful subcutaneous lipomas, chronic diffuse adipose tenderness, and associated neuropsychiatric or systemic symptoms.

The prognosis of adiposis dolorosa is typically chronic and relapsing, although it is not life-threatening. The condition is not associated with malignant transformation of lipomas; however, it is marked by progressive pain, functional limitations, and diminished quality of life. While mortality is not directly increased, morbidity remains substantial due to chronic pain, metabolic comorbidities, and the accompanying psychosocial burden. Early diagnosis and coordinated, multidisciplinary management—encompassing pain specialists, psychiatrists, endocrinologists, surgeons, and rehabilitation teams—are vital for optimizing symptom control, maintaining mobility, and preventing disability. Long-term supportive care is essential, with the therapeutic focus centered on symptom relief and quality of life rather than disease eradication. With comprehensive, patient-centered management, individuals may achieve improved function and better overall well-being despite the chronic nature of the disorder.

Adiposis dolorosa is not life-threatening, but it is associated with significant morbidity. The most common complication is chronic pain, which is often severe, disabling, and resistant to conventional therapy. Persistent pain contributes to functional impairment, reduced mobility, and loss of independence in daily activities. Psychiatric comorbidities are frequent, including depression, anxiety, and cognitive difficulties, often worsened by sleep disruption and chronic fatigue. These symptoms further impair quality of life and may complicate management. Surgical interventions, such as liposuction or lipectomy, can provide temporary relief but carry risks of recurrence, scarring, infection, and procedural complications. Additionally, patients with obesity or metabolic syndrome are at risk for cardiovascular disease, diabetes, and other obesity-related complications, which may overlap with the burden of adiposis dolorosa. Finally, the psychosocial burden of chronic pain and visible lipomas can result in social withdrawal, unemployment, and reduced overall quality of life. Effective multidisciplinary care is crucial in mitigating these long-term complications.

Patients with adiposis dolorosa benefit most from a coordinated, multidisciplinary approach, particularly when the pain is severe or disabling. Collaboration across specialties ensures that the disease's physical and psychosocial aspects are addressed. Pain management specialists are often central to care, guiding multimodal pharmacologic and interventional strategies. Psychiatrists and psychologists help manage depression, anxiety, and cognitive difficulties that commonly accompany chronic pain. Dermatologists or surgeons can assess lipomas and determine the suitability of surgical intervention, while endocrinologists provide expertise when metabolic or endocrine abnormalities coexist. Physical and occupational therapy teams support patients by enhancing mobility, function, and overall independence. Collectively, this multidisciplinary coordination enhances quality of life, mitigates long-term morbidity, and supports sustainable symptom control in this chronic, relapsing condition.

Currently, there are no established preventive strategies for adiposis dolorosa because its etiology and risk factors remain poorly defined. Patients should be counseled that this chronic condition often requires long-term management rather than curative treatment. Education should emphasize the importance of a multidisciplinary care model, including pain management, mental health support, physical rehabilitation, and, when appropriate, surgical consultation. Patients should be informed that while interventions such as liposuction, lipectomy, or analgesic regimens may provide temporary symptom relief, recurrence is common, and expectations must be realistic. Psychological support is vital, as many patients experience depression, anxiety, or cognitive difficulties due to chronic pain and disability. Counseling should reinforce that these symptoms are a natural part of the disease process and not a sign of personal weakness, thereby helping to reduce stigma. Patients may also benefit from support groups and educational resources to enhance coping strategies and reduce social isolation. Encouraging healthy lifestyle measures, including weight optimization, balanced nutrition, and physical activity as tolerated, may help improve functional status and address metabolic comorbidities, even though they do not reverse the underlying condition.

Managing adiposis dolorosa requires an interprofessional, patient-centered model that integrates the disease's chronic pain, psychiatric, and metabolic dimensions. Primary care clinicians play a central role in establishing accurate diagnoses, excluding mimicking conditions, and coordinating individualized treatment plans that balance pharmacologic, procedural, and surgical options. Ethically, they must weigh therapeutic innovation—such as off-label pharmacologic or surgical interventions—against patient safety, set realistic expectations, and avoid unnecessary or harmful procedures. Nurses support continuity of care through patient education, monitoring treatment response, reinforcing adherence, and facilitating clinician communication. Their ongoing contact with patients positions them to identify early signs of clinical deterioration or psychosocial stress. Pharmacists enhance safety and efficacy by reviewing complex pain regimens, minimizing polypharmacy, and ensuring appropriate use of opioids and adjuvant agents. Mental health professionals address depression, anxiety, and cognitive symptoms that often undermine quality of life and functional capacity. Rehabilitation specialists, including physical and occupational therapists, promote mobility, functional independence, and self-efficacy through personalized, adaptive interventions. Effective interprofessional communication—through structured strategies such as team huddles, shared decision-making, and evidence-based pain protocols—helps reduce fragmentation, prevent redundant therapies, and enhance patient safety. A collaborative, ethically grounded, and multidisciplinary approach can reduce morbidity, improve function, and enhance patient outcomes and team performance in managing adiposis dolorosa.